Details for New Drug Application (NDA): 020121
NDA 020121 describes FLONASE, which is a drug marketed by Haleon Us Holdings and is included in three NDAs. There are three patents protecting this drug. Additional details are available on the FLONASE profile page.
The generic ingredient in FLONASE is fluticasone furoate. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
The generic ingredient in FLONASE is fluticasone furoate. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for 020121
| Tradename: | FLONASE |
| Applicant: | Haleon Us Holdings |
| Ingredient: | fluticasone propionate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Oct 19, 1994 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
